Dramatic complete metabolic response on 18 FFDG positron emission tomography/computed tomography after bispecific antibody therapy in CAR-T refractory diffuse large B-cell lymphoma (EANM 2026) - Sep 29, 2026 - Abstract #EP-1364; "Materials and A 56-year-old male with Epstein-Barr virus-positive diffuse large B-cell lymphoma (DLBCL), stage IVB, initially treated with R-CHOP, experienced relapse and subsequently underwent CAR-T therapy... 18F-FDG PET/ CT is a pivotal tool for response assessment in patients with lymphoma treated with advanced immunotherapies. This case highlights the potential for profound metabolic remission even in CAR-T refractory disease and underscores the value of PET/CT in guiding clinical decision-making. Careful interpretation of residual low-level uptake is essential to avoid misclassification in this setting."
Bispecific • CAR T-Cell Therapy • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Epstein-Barr Virus Infections • Hematological Malignancies • Hepatology • Lymphoma • Metabolic Disorders • Non-Hodgkin's Lymphoma
|
|
E. Moratalla-Aranda; S. Martin Aguilar; M. Sanchez Torrente; L. Mena Bares; M. Ureña Lara
|